• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$90.53 $0.04 (0.04%)

REAL-TIME: Last trade at

Allergan, Inc.

NYSE:AGN

Critical Alerts For Chevron, EMC, F5 Networks, Allergan, and Kinross Gold Released By InvestorsObserver

Botox lawsuit that asked $60.5 million settles

OpenText Customer to Highlight Success Story at Gartner Enterprise Architecture Summit

Oversold Market Leads to Opportunities (SPY, AGN, PM, AAPL)

Not a dry eye in the house

Ex-Dividend Stocks: Thomson Reuters, Infosys

Allergan Inc. to Build R&D Plant, Add 400 Jobs in New Jersey

Allergan management to meet with Bernstein

Allergan to open R&D plant in New Jersey

Allergan Inc. Signs for 93,000 SF in Somerset Corporate Center II

NICE Rec for Allergan's Botox - Analyst Blog

NICE Rec for Allergan's Botox

Global Botulinum Toxin Industry

BofA/Merrill's Head of U.S. Equity & Quantitative Strategy holds conference call

National Institute for Clinical Excellence (NICE) Backs Allergan Inc.''s Botox for Some Migraine Sufferers

Amakem Appoints Dr. Steve Pakola as Chief Medical Officer; Dr. George Lasezkay Joins Board of Directors

L’Oreal Loses European Union Court Challenge Over Botox-Like Trademarks

Cramer's 'Mad Money' Recap: 7 Stocks to Scoop Up When On Sale

Allergan Hit with Federal Subpoena Over Lap-Band Weight Loss Device

Government Subpoenas Allergan on Lap-Band

Wells Fargo's healthcare analyst discusses Allergan's botox on a conference call

Allergan receives U.S. subpoena over weight-loss device

Touch of Life Technologies' New Cystoscopy and Bladder Injection Simulator Offers Urologists Training on Use of BOTOX(R) (onabotulinumtoxinA) as Treatment for Urinary Incontinence in Adults With Neurological Conditions

U.S. subpoenas Allergan over gastric banding device, Bloomberg reports

ALLERGAN LAUNCHES TRIPLE ACTION OPTIVE PLUS® EYEDROPS FOR THE TREATMENT OF DRY EYES

Allergan 1Q Profit Rises 45%

Allergan sell off overdone, says Susquehanna

Allergan sell-off unwarranted, says RBC Capital

Allergan's Profit Rises 45% on Stronger Botox Sales

Allergan Management Discusses Q1 2012 Results - Earnings Call Transcript

24/7 Wall St. Closing Bell (CHK, COP, RSH, STM, AIZ, ABX, MRO, MA, AGN, AUY, TWX, CLX, RDC, RRD, MSO, IACI, FSLR, DSX, COCO, APA, OWW, WNR, CMCSA, SVNT)

Allergan in Line on Profit; Shares Fall on Q2 Forecast

Allergan Beats on Revs, Misses on EPS

Allergan says "always looking" for licenses, acquisitions

Allergan likely to extend 10b5-1 program, continue with open market purchases

Allergan continues to implement targeted investments to support future growth

Allergan Reports First Quarter 2012 Operating Results

Allergan believes no generic of Sanctura XR will be commercialized during 2012

Allergan weakness a buying opportunity, says Citigroup

Allergan says U.S. healthcare reform to cost company about $110M in 2012

See More Articles...